Clinical trial
Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients
NCT00386373 · M.D. Anderson Cancer Center, Other · Completed
Key facts
| NCT number | NCT00386373 |
|---|---|
| Title | Use and Tolerability of Imatinib Mesylate (Gleevec) in Leukemia Patients |
| Official title | Use and Tolerability of Imatinib Mesylate (Gleevec®) in Patients With Philadelphia-Positive Chronic Myeloid or Acute Leukemia During the First 100 Days Following Bone Marrow or Stem Cell Transplantation |
| Lead sponsor | M.D. Anderson Cancer Center, Other |
| Status | Completed |
| Study type | Interventional |
| Conditions | Leukemia |
| Intervention type | Drug |
| Interventions | Imatinib Mesylate |
| Enrollment | 10 |
| Start date | Aug 1, 2003 |
| Primary completion | Oct 1, 2007 |
| Completion | Oct 1, 2007 |
| First posted | Oct 11, 2006 |
| Last update posted | Aug 1, 2012 |
| Countries | United States |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: